Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesA. Michael Lincoff, Donna H. Ryan, Kirstine Brown‐Frandsen et al.|New England Journal of Medicine|2023Cited by 2.6k
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis SocietyOlov Wiklund, Albert Wiegman, M. John Chapman et al.|European Heart Journal|2014Cited by 1.1k
Evinacumab for Homozygous Familial HypercholesterolemiaFrederick J. Raal, Daniel Gaudet, Robert S. Rosenson et al.|New England Journal of Medicine|2020Cited by 763
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialFrederick J. Raal, Daniel Gaudet, Evan A. Stein et al.|The Lancet|2014Cited by 750
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and managementRobert A. Hegele, Olov Wiklund, Henry N. Ginsberg et al.|The Lancet Diabetes & Endocrinology|2013Cited by 632